Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells $19,550.00 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 2,500 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $7.82, for a total transaction of $19,550.00. Following the completion of the sale, the chief executive officer now owns 120,695 shares of the company’s stock, valued at approximately $943,834.90. This trade represents a 2.03 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Richard Nolan Townsend also recently made the following trade(s):

• On Thursday, October 10th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $8.10, for a total value of $40,500.00.
• On Tuesday, September 10th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $10.65, for a total value of $53,250.00.

Lexeo Therapeutics Stock Performance

Shares of LXEO stock opened at $6.65 on Friday. The firm’s 50 day moving average is $9.01 and its 200 day moving average is $12.23. The stock has a market capitalization of $219.85 million and a P/E ratio of -2.10. Lexeo Therapeutics, Inc. has a 12 month low of $6.65 and a 12 month high of $22.33. The company has a current ratio of 9.38, a quick ratio of 9.38 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On Lexeo Therapeutics

Institutional investors have recently made changes to their positions in the stock. Frazier Life Sciences Management L.P. purchased a new stake in shares of Lexeo Therapeutics in the third quarter worth about $11,307,000. RA Capital Management L.P. purchased a new stake in Lexeo Therapeutics in the 1st quarter worth approximately $10,364,000. Janus Henderson Group PLC boosted its holdings in Lexeo Therapeutics by 18.9% in the 3rd quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock valued at $33,997,000 after purchasing an additional 599,203 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Lexeo Therapeutics during the 3rd quarter valued at $3,348,000. Finally, Verition Fund Management LLC increased its holdings in shares of Lexeo Therapeutics by 84.5% in the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock worth $7,027,000 after purchasing an additional 355,928 shares during the period. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on LXEO shares. HC Wainwright lifted their target price on Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday. Chardan Capital raised their price objective on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday, August 13th. Finally, Leerink Partners decreased their price target on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Wednesday. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Lexeo Therapeutics has a consensus rating of “Buy” and an average price target of $22.71.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.